Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...
If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...
Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish ...
ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...
Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback